US FDA approves first biosimilar, keeps quiet on naming standards

09-03-2015

US FDA approves first biosimilar, keeps quiet on naming standards

Poprotskiy Alexey / Shutterstock.com

The US Food and Drug Administration (FDA) approved Sandoz’s cancer product Zarxio (filgrastim-sndz) on Friday (March 6)—the first biosimilar to be rubber stamped in the US.


Zarxio, biosimilar, FDA, Sandoz, BPCIA, filgrastim, Zarzio

LSIPR